Search

Your search keyword '"Carroll, Miles"' showing total 805 results

Search Constraints

Start Over You searched for: Author "Carroll, Miles" Remove constraint Author: "Carroll, Miles"
805 results on '"Carroll, Miles"'

Search Results

1. Serological analysis in humans in Malaysian Borneo suggests prior exposure to H5 avian influenza near migratory shorebird habitats

4. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

5. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

6. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

7. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

8. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

9. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients

10. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

11. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea

13. Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy

14. Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

15. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2

16. Divergent trajectories of antiviral memory after SARS-CoV-2 infection

17. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

18. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

19. Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

20. Serological analysis in humans in Malaysian Borneo suggests prior exposure to H5 avian influenza

21. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks

22. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study

23. Virus genomes reveal factors that spread and sustained the Ebola epidemic

24. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

25. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

26. Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

27. Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes

28. Rvsv-Zebov Vaccination in People with Pre-Existing Immunity to Ebolavirus: An Open-Label Safety and Immunogenicity Study in Guinean Communities Affected by Ebola Virus Disease (L’Essai Proches)

29. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

32. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

33. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

34. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

36. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

37. Animal models for COVID-19

38. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

39. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

41. Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents

45. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

47. Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child

48. Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members

49. Predicting the past and future evolutionary space of SARS-CoV-2

50. A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

Catalog

Books, media, physical & digital resources